Targeting the poly (ADP-ribose) pathway holds great promise as an approach to anti-cancer therapy, and some success has been met using PARP1/2 inhibitors (PARPiS) to treat cancers harboring defects in the homologous recombination repair pathway, especially BRCA1/2 mutated tumors. This evidence concerns the gene BRCA1 and cancer.